États-Unis · Bourse & Finance · Yahoo Finance

Johnson & Johnson (JNJ) Reports Sustained Phase 3 Skin Clearance For ICOTYDE

Publié par Yahoo Finance · États-Unis il y a 10 h

Johnson & Johnson (NYSE: JNJ) reported new Phase 3 results for oral peptide ICOTYDE in plaque psoriasis at the 2026 EADV Congress. The oral IL-23 inhibitor showed sustained skin…

Lire l'article complet sur Yahoo Finance Connectez-vous pour sauvegarder

MediaNews présente le titre et le résumé publiés par le média. L'article complet se lit sur le site de l'éditeur. (finance.yahoo.com)

Johnson & Johnson (JNJ) Reports Sustained Phase 3 Skin Clearance For ICOTYDE

À lire aussi

Federal judge calls Flock ‘indiscriminate mass surveillance’

Key deals this week: Onsemi, Mattel, Nebius, Advanced Micro Devices, and more

OpenAI leader who quit says he can do more for safety from outside the company

Iran Is Losing Some of Its Leverage Over the Strait of Hormuz

High mortgage rates are trapping homeowners in place, and making renovations harder to afford

U.S. debt is increasingly at the mercy of the market as interest costs surge while elections add more risk to the debt ceiling, ratings agency warns

Johnson & Johnson (JNJ) Reports Sustained Phase 3 Skin Clearance For ICOTYDE

Partager

À lire aussi

Federal judge calls Flock ‘indiscriminate mass surveillance’

Key deals this week: Onsemi, Mattel, Nebius, Advanced Micro Devices, and more

OpenAI leader who quit says he can do more for safety from outside the company

Iran Is Losing Some of Its Leverage Over the Strait of Hormuz

High mortgage rates are trapping homeowners in place, and making renovations harder to afford

U.S. debt is increasingly at the mercy of the market as interest costs surge while elections add more risk to the debt ceiling, ratings agency warns